Peptides
ARA-290
ARA-290 is an erythropoietin-derived peptide studied in nerve and inflammation research. Below, we compare vendors currently stocking research-grade ARA-290 — not just a single sales page.
ARA-290 is an erythropoietin-derived peptide studied in nerve and inflammation research. Below, we compare vendors currently stocking research-grade ARA-290 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 Amino VaultBest Value |
$68.85 | Third-party COA | Buy Here → | |
 American Peptides |
$82.00 | Third-party COA | Buy Here → |
ARA-290 (Cibinetide) is a synthetic peptide derived from the structure of erythropoietin (EPO), engineered to retain EPO's tissue-protective signaling while eliminating its blood-cell-stimulating (hematopoietic) activity.
Research-grade ARA-290 is typically supplied as a lyophilized powder in sealed vials, commonly at 10mg to 15mg strengths, intended for laboratory research use.
ARA-290 selectively activates the innate repair receptor (a complex of the EPO receptor and CD131), a pathway distinct from the classical EPO receptor responsible for red blood cell production, which is why researchers describe it as a non-hematopoietic EPO derivative.
ARA-290 has been studied in human clinical trials for neuropathic pain associated with conditions such as sarcoidosis and diabetes, representing one of the more clinically developed compounds in this category.
Beyond pain research, ARA-290 has been studied for effects on metabolic parameters and tissue protection in models of chronic inflammatory conditions, reflecting the innate repair receptor's broader proposed role in cellular stress response.
ARA-290/Cibinetide has completed multiple human clinical trials with published safety data indicating it is generally well-tolerated at studied doses; it has not, however, received full FDA approval for a marketed indication, and research-grade material outside those regulated trials has not undergone the same quality controls.
Doses used in published clinical trials are documented in that trial literature and are specific to those regulated study protocols; no FDA-approved commercial dosage exists for ARA-290 research material.
Compound X does not sell ARA-290 directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
ARA-290/Cibinetide clinical trial data is indexed on PubMed under "ARA290 Cibinetide innate repair receptor" and "erythropoietin derivative neuropathic pain."
New guides, vendor comparisons and compound breakdowns every week.